Veterinary pharmacovigilance market seen reaching $1.67 billion by 2030

By AI, Created 10:53 AM UTC, May 20, 2026, /AGP/ – The veterinary pharmacovigilance market is projected to grow from $0.91 billion in 2025 to $1.67 billion by 2030, driven by tighter safety rules, higher animal health spending and more outsourcing. North America held the largest share in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Veterinary pharmacovigilance is becoming more important as regulators and animal health companies place more emphasis on monitoring medicine safety after approval. - The market is tied to real-world demand for safer veterinary drugs, better adverse event reporting and broader animal health oversight. - Growth in the market signals more spending on post-marketing safety work across pets and livestock.

What happened: - The Business Research Company said the veterinary pharmacovigilance market is projected to rise from $0.91 billion in 2025 to $1.03 billion in 2026. - The same forecast puts the market at $1.67 billion by 2030, implying a 12.7% compound annual growth rate over the forecast period. - North America held the largest share of the global market in 2025. - Asia-Pacific is expected to be the fastest-growing region through 2030. - The market analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - Download a free sample of the report. - View the full market report.

The details: - Veterinary pharmacovigilance is the science of detecting, evaluating and preventing adverse effects or other drug-related issues in animals. - The field focuses on monitoring the safety and efficacy of veterinary medicines after approval for use. - The main objective is to ensure benefits outweigh risks while protecting animal health, human health and the environment. - The market’s recent growth is linked to the lack of formal veterinary pharmacovigilance frameworks, rising veterinary drug use, higher companion-animal healthcare spending, more reports of adverse drug reactions and tighter safety rules. - Demand is being lifted by stronger global veterinary drug regulations, more biologics and anti-infectives, growing outsourcing of pharmacovigilance work, real-time safety monitoring needs and larger livestock and companion-animal populations. - The report highlights trends including more regulatory scrutiny, wider use of outsourced services, stronger post-marketing surveillance, better adverse event reporting systems and greater veterinarian awareness of drug safety. - The report says rising demand for animal health products and medicines is a key growth driver. - Pet ownership growth, veterinary care advances and pressure to improve livestock productivity are increasing consumption of pet food, medications and grooming supplies. - Animal welfare awareness and the rising prevalence of animal diseases are also supporting demand. - Estonia’s Agency of Medicines reported 6.9% growth in the veterinary medicinal products sector in 2023, reaching 18.6 million euros from 17.4 million euros in 2022.

Between the lines: - The forecast points to a broader shift from reactive treatment to ongoing drug safety surveillance in animal health. - Outsourced pharmacovigilance services appear to be gaining traction as companies and regulators face more reporting and monitoring demands. - The regional split suggests mature markets are already large, while emerging markets may be adding new growth as animal health spending expands.

What’s next: - The market is expected to keep expanding through 2030 as safety rules tighten and monitoring systems become more sophisticated. - More demand should follow from biologics development, anti-infective use and broader adoption of real-time adverse event tracking. - Regulatory teams and veterinary drug makers will likely face more pressure to improve post-market surveillance and reporting infrastructure.

The bottom line: - Veterinary pharmacovigilance is moving from a niche compliance function to a bigger global animal-health priority, with the market on track to nearly double by 2030.